Theophylline and fibrocystic breast disease.
After literature reports linking fibrocystic breast disease (FBD) to methylxanthine ingestion, a pilot study was undertaken to investigate the possible contribution of theophylline to this effect. The major goal of this project was to measure the effect of theophylline therapy on FBD in asthmatic women. All women attending an allergy clinic or an obstetrics/gynecology clinic over a 9-month period were examined to clinically assess FBD and were asked to complete a detailed questionnaire covering health history, other risk factors, and drug and dietary methylxanthines. The sample included 62 asthmatic women, 66 allergic but not asthmatic women, and 72 nonallergic and nonasthmatic women. By use of the FBD clinical taxonomy with its 19-point scale going from 0 to 18 that was developed for this study, the three groups did not differ significantly in terms of mean severity of FBD. On analyzing the effect of each of the methylxanthines on FBD severity, there is clear evidence that total methylxanthines was a contributing factor in FBD severity with or without adjustment for relevant variables, such as age, menopause, pregnancies, and groups. Theophylline was significant only when adjustments were made for age, pregnancy, and menopause in contrast to caffeine that was only significant with no adjustments.
D000328:Adult; D000367:Age Factors; D001249:Asthma / Q000150:complications* / Q000188:drug therapy; D002110:Caffeine / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D005348:Fibrocystic Breast Disease / Q000139:chemically induced / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D011247:Pregnancy; D012306:Risk; D013806:Theophylline / Q000009:adverse effects* / Q000627:therapeutic use; D014970:Xanthines / Q000009:adverse effects
D004967:Estrogens; D014970:Xanthines; C008514:methylxanthine; D002110:Caffeine; D013806:Theophylline